FDA’s food safety head resigns over mass layoffs
Jim Jones, the head of the Food and Drug Administration’s (FDA) food division, resigned Monday, citing the mass firings of ...
Global Transmucosal Drugs Market to Reach ~USD 28 Billion by 2032 | DelveInsight
DelveInsight's Transmucosal Drugs Market Insights report provides the current and forecast market analysis, individual ...
What new DOGE firings at the FDA could mean for food safety and medical devices
The firings appeared to focus on employees in the agency’s centers for food, medical devices, and tobacco products. The Trump ...
redstateobserver3h
FDA Leadership Change Reflects Trump's Commitment to Food Safety
Crucial Leadership Shakeup at FDA Signals Shift Under Trump Administration** In a striking move that underscores the ongoing transformation at the Food and Drug Administration ( ...
F.D.A.’s Food Safety Chief Resigns Over Trump Administration Layoffs
The chief said the loss of critical employees overseeing the nation’s food supply made his work impossible. Robert F. Kennedy ...
STAT5h
FDA’s former top food official says Trump firings are ‘dismantling’ the division
The former head of the FDA's food division told STAT he resigned because cuts made by the Trump administration imperil the ...
Leader of FDA food division resigns
Jim Jones’ resignation comes after the Trump administration last week cut thousands of federal workers, including some at the ...
Environmental Defense Fund7h
Resignation of Food and Drug Administration Leader Is a Setback for Safety of U.S. Food System
(WASHINGTON, D.C. – February 18, 2025) The head of the Food and Drug Administration, Jim Jones, announced his resignation today, citing far-reaching staff cuts at the agency.
AZoNano8h
Promising New Platform for Brain-Targeted mRNA Delivery
Innovative lipid nanoparticles enable mRNA delivery to the brain, offering new avenues for treating neurological disorders by crossing the blood-brain barrier.
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
VIVOZON Pharmaceutical Obtains MFDS Approval for UNAFRA Inj.: A Breakthrough Non-Opioid analgesic
VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, 2024.
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...